financetom
Business
financetom
/
Business
/
Form 8.3 - Greencore Group PLC
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Form 8.3 - Greencore Group PLC
Sep 15, 2025 4:12 AM

LONDON--(BUSINESS WIRE)--

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

Qube Research & Technologies Limited

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Greencore Group PLC ( GNCGF )

If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

12-09-2025

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

Bakkavor Group PLC

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

 

1p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

0

0.00

(2) Cash-settled derivatives:

 

6,447,930

1.45

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

 

TOTAL:

6,447,930

1.45

0

0.00

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

0

Details, including nature of the rights concerned and relevant percentages:

0

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit (GBp)

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. call option

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of securities

Exercise price per unit (GBp)

1p ordinary

equity swap

decreasing a long position

1396

241.50

1p ordinary

equity swap

decreasing a long position

65207

244.00

1p ordinary

equity swap

decreasing a long position

2187

244.25

1p ordinary

equity swap

decreasing a long position

3263

244.50

1p ordinary

equity swap

decreasing a long position

7950

245.00

1p ordinary

equity swap

decreasing a long position

1246

245.50

1p ordinary

equity swap

decreasing a long position

3

246.50

1p ordinary

equity swap

decreasing a long position

1982

247.00

1p ordinary

equity swap

decreasing a short position

221

244.00

1p ordinary

equity swap

increasing a long position

1

242.00

1p ordinary

equity swap

increasing a long position

723

248.75

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit (GBp)

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit
(GBp)

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

0

0

0

0

 

0

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

0

 

0

0

0

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

None

 

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

 

None

 

(c) Attachments

Class of relevant security:

 

1p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

0

0.00

(2) Cash-settled derivatives:

 

6,447,930

1.45

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

 

TOTAL:

6,447,930

1.45

0

0.00

0

Class of relevant security:

 

1p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

0

0.00

(2) Cash-settled derivatives:

 

6,447,930

1.45

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

 

TOTAL:

6,447,930

1.45

0

0.00

1

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Source: Qube Research & Technologies LTD

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Satellos Bioscience Forms Advisory Board to Advance SAT-3247 in Duchenne Muscular Dystrophy Treatment
Satellos Bioscience Forms Advisory Board to Advance SAT-3247 in Duchenne Muscular Dystrophy Treatment
May 28, 2024
07:37 AM EDT, 05/28/2024 (MT Newswires) -- Satellos Bioscience ( MSCLF ) on Tuesday said it has formed a clinical advisory board comprised of clinical research and drug development experts in genetic muscle disorders, including Duchenne muscular dystrophy. The formation of this clinical advisory board marks a major development step for Satellos as we continue our evolution in becoming a...
Nordson to Buy Atrion for $460 per Share
Nordson to Buy Atrion for $460 per Share
May 28, 2024
07:37 AM EDT, 05/28/2024 (MT Newswires) -- Nordson ( NDSN ) said Tuesday it has agreed to buy Atrion ( ATRI ) for $460 per share in cash, representing an enterprise value of roughly $800 million. The company, which plans to finance the transaction through cash on hand and newly issued financial debt, said it expects deal completion before its...
J&J acquires rights to skin disorder drug for $1.25 bln
J&J acquires rights to skin disorder drug for $1.25 bln
May 28, 2024
May 28 (Reuters) - Johnson & Johnson ( JNJ ) said on Tuesday that it had agreed to acquire the rights to an experimental skin disorder treatment from privately held Numab Therapeutics for about $1.25 billion. J&J will acquire Numab's unit for the global rights to the drug, called NM26. (Reporting by Christy Santhosh in Bengaluru; Editing by Anil D'Silva)...
Market Chatter: PayPal Planning to Build Ad Business
Market Chatter: PayPal Planning to Build Ad Business
May 28, 2024
07:36 AM EDT, 05/28/2024 (MT Newswires) -- PayPal Holdings ( PYPL ) is planning to build an ad sales business around the data it generates from tracking the purchases and spending behaviors of the millions of consumers who use its services, The Wall Street Journal reported Tuesday. (Market Chatter news is derived from conversations with market professionals globally. This information...
Copyright 2023-2026 - www.financetom.com All Rights Reserved